Cell and Tissue Engineering

Fraunhofer Institute for Interfacial Engineering and Biotechnology

Focus

The core competence of the Cell and Tissue Engineering Department is the development of functional 3D tissue models in vitro from isolated primary human cells. With these tissue models, we help solve complex challenges in the areas of regenerative medicine, tissue engineering and the development of cell-based assays for toxicology. We develop biocompatible micro- and nano-structured material surfaces for the effective isolation and culture of primary cells and for optimal cell type-specific cultivation, in particular of adult stem cells. The physiological cultivation of our 3D tissue models is made possible by computer-controlled bioreactor systems designed specifically for the cell type in question. Sterility testing and quality control of cell-based transplants is a laborious process which always requires two graft samples – one for testing and one for transplantation. We are therefore in the process of establishing a non-invasive reference method based on Raman spectroscopy.

A two-layered human 3D skin equivalent has been patented (EP 1 290 145B1) and accredited for the testing of the biocompatibility of medicinal devices (DIN ISO 10993-5). The skin model can be extended by further cell types such as melanocytes or tumor cells. It is also suitable – as a preliminary stage to animal testing – in investigations of the penetration and the distribution of test substances, as required by the European Union chemicals regulation REACH. The model’s scope extends to investigation of differentiation, apoptosis, and also of tumor initiation and graduation. We have recently succeeded in integrating vascular structures (blood vessel equivalents) into the skin model. In addition, in 2010 we were able to automate the complete process for manufacturing the avascular skin model.

A further focus is the miniaturization and the characterization of our 3D intestinal testing system. Our accredited two-dimensional intestinal assay based on colon carcinoma cells (2D Caco-2 model) allows validated permeability and transport studies of potential candidate drugs and other substances at the intestinal barrier.

We have also been able to establish GMP conditions for the cultivation of our vascularized matrix (BioVaSc) in specific bioreactors. This matrix is used to generate complex organ structures. As part of a project funded by the German Federal Ministry of Education and Research (BMBF) we are currently preparing the first clinical study of a trachea transplant based on the BioVaSc.